Medicare Enrolled

Dr. Raji Shameem, M.D.

Hematology · Orlando, FL
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Speaking/Promotional
7472 DOCS GROVE CIR, Orlando, FL 32819
4072411037
In practice since 2011 (14 years)
NPI: 1356631287 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Shameem from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Shameem? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Shameem

Dr. Raji Shameem is a hematology specialist in Orlando, FL, with 14 years of NPI registration. Based on federal Medicare data, Dr. Shameem performed 39,042 Medicare services across 1,757 unique beneficiaries.

Between the years covered by Open Payments, Dr. Shameem received a total of $668,012 from 93 pharmaceutical and/or device companies across 1204 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Shameem is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 14 years in practice ▲ 39,042 Medicare services $668,012 industry payments

Medicare Practice Summary

Medicare Utilization ↗
39,042
Medicare services
Bottom 32% in FL for hematology
Lower Medicare volume may reflect subspecialty focus, hospital-based work, or a higher share of non-Medicare patients.
1,757
Unique beneficiaries
$6
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~2,789 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Iron infusion (Feraheme) 10,200 $0 $4
Filgrastim injection (Zarxio) for white blood cells 8,580 $0 $2
Iron sucrose injection (Venofer) 8,400 $0 $5
Denosumab injection (Prolia/Xgeva) 4,500 $18 $46
Epoetin alfa injection (Retacrit) for anemia 1,220 $6 $21
Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg 1,150 $24 $163
Dexamethasone injection (steroid) 900 $0 $3
Complete blood count (CBC) with differential 512 $8 $29
Blood draw (venipuncture) 471 $8 $9
Anti-nausea injection (Aloxi/palonosetron) 470 $1 $30
Office visit, established patient (20-29 min) 356 $64 $207
Drug injection, under skin or into muscle 355 $9 $66
Anti-nausea injection (ondansetron/Zofran) 344 $0 $15
Injection of additional new drug or substance into vein 192 $11 $76
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg 162 $1 $6
Administration of chemotherapy into vein, 1 hour or less 144 $94 $407
Injection, zoledronic acid, 1 mg 138 $7 $68
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less 121 $46 $206
Office visit, established patient (30-39 min) 98 $90 $319
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle 86 $53 $185
Administration of chemotherapy into vein, each additional hour 83 $20 $100
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less 72 $21 $142
Injection, diphenhydramine hcl, up to 50 mg 70 $1 $3
Administration of additional new drug or substance into vein, 1 hour or less 51 $48 $176
Infusion into a vein for therapy, prevention, or diagnosis, each additional hour 50 $15 $86
Injection of drug or substance into vein 43 $26 $155
New patient office visit (45-59 min) 40 $99 $429
Infusion, normal saline solution, sterile (500 ml = 1 unit) 40 $1 $9
Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle 36 $23 $93
Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional 30 $17 $59
Initial hospital admission, moderate complexity 30 $99 $384
Infusion into a vein for hydration, 31-60 minutes 27 $24 $170
Hospital follow-up visit, high complexity 27 $94 $346
Hospital follow-up visit, moderate complexity 19 $59 $199
Initial hospital admission, high complexity 13 $131 $549
Irrigation of implanted venous access drug delivery device 12 $19 $67
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
26.9% high complexity
68.8% medium
4.2% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$668,012
Total received (2018-2024)
Avg $95,430/year across 7 years
Top 1% in FL for hematology
93
Companies
1,204
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$617,079 (92.4%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$36,488 (5.5%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$14,146 (2.1%)
Other
Charitable contributions, space rental, and other categories
$299 (0.0%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$497,268
2023
$144,869
2022
$12,584
2021
$3,088
2020
$7,286
2019
$2,287
2018
$629

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
SOBI, INC
$191,963
Takeda Pharmaceuticals U.S.A., Inc.
$116,419
Ipsen Biopharmaceuticals, Inc
$104,794
E.R. Squibb & Sons, L.L.C.
$80,175
GlaxoSmithKline, LLC.
$41,714
BeiGene USA, Inc.
$29,500
Eisai Inc.
$15,730
JAZZ PHARMACEUTICALS INC.
$15,197
Exelixis Inc.
$12,256
PFIZER INC.
$11,129
Novocure Inc.
$6,075
Incyte Corporation
$4,744
Agios Pharmaceuticals, Inc.
$4,357
Pharmacosmos Therapeutics Inc.
$3,616
Rigel Pharmaceuticals, Inc.
$3,418
ABBVIE INC.
$2,714
AstraZeneca Pharmaceuticals LP
$2,350
TAIHO ONCOLOGY, INC.
$2,162
Seagen Inc.
$2,148
Janssen Scientific Affairs, LLC
$1,791
Celgene Corporation
$1,737
Adaptive Biotechnologies Corporation
$1,708
Gilead Sciences, Inc.
$1,672
Astellas Pharma US Inc
$1,243
Sobi, Inc
$1,231
Novartis Pharmaceuticals Corporation
$1,153
Janssen Biotech, Inc.
$1,021
GENZYME CORPORATION
$559
BeiGene, Ltd.
$450
Genentech USA, Inc.
$383
Amgen Inc.
$366
Daiichi Sankyo Inc.
$319
NOVARTIS PHARMACEUTICALS CORPORATION
$299
Pharmacyclics LLC, An AbbVie Company
$205
Taiho Oncology, Inc.
$203
ARRAY BIOPHARMA INC
$194
Merck Sharp & Dohme LLC
$193
Lilly USA, LLC
$181
Boehringer Ingelheim Pharmaceuticals, Inc.
$163
Mirati Therapeutics, Inc.
$146
Bayer HealthCare Pharmaceuticals Inc.
$146
Karyopharm Therapeutics Inc.
$123
Octapharma USA, Inc.
$113
Merck Sharp & Dohme Corporation
$110
Kite Pharma, Inc.
$96
Global Blood Therapeutics, Inc.
$96
Foundation Medicine, Inc.
$86
Alexion Pharmaceuticals, Inc.
$86
TerSera Therapeutics LLC
$85
Array BioPharma Inc.
$69
Dendreon Pharmaceuticals LLC
$65
SUN PHARMACEUTICAL INDUSTRIES INC.
$60
Heron Therapeutics, Inc.
$60
EMD Serono, Inc.
$55
Alnylam Pharmaceuticals Inc.
$53
G1 Therapeutics, Inc.
$52
AMAG Pharmaceuticals, Inc.
$51
AbbVie Inc.
$48
MEDIVATION FIELD SOLUTIONS LLC
$47
CTI BioPharma Corp.
$46
Bayer Healthcare Pharmaceuticals Inc.
$46
RECORDATI_RARE_DISEASES_INC.
$41
ADC Therapeutics America, Inc.
$38
Inari Medical, Inc.
$38
Sumitomo Pharma America, Inc.
$37
Pharmacyclics LLC, an AbbVie Company
$32
PUMA BIOTECHNOLOGY, INC.
$32
Deciphera Pharmaceuticals Inc.
$31
Jazz Pharmaceuticals Inc.
$29
Blueprint Medicines Corporation
$29
Dova Pharmaceuticals
$25
Myovant Sciences Inc.
$25
Stemline Therapeutics Inc.
$24
Kyowa Kirin, Inc.
$24
Regeneron Healthcare Solutions, Inc.
$24
Acrotech Biopharma LLC
$24
Clovis Oncology, Inc.
$24
TG Therapeutics, Inc.
$23
SECURA BIO, INC.
$23
AVEO Pharmaceuticals, Inc.
$23
EISAI INC.
$22
Apellis Pharmaceuticals, Inc.
$21
Servier Pharmaceuticals LLC
$19
MACROGENICS, INC.
$19
Puma Biotechnology, Inc.
$18
Aurobindo Pharma USA, Inc.
$14
GT Medical Technologies, Inc
$13
EUSA Pharma (US) LLC
$13
Helsinn Therapeutics (U.S.), Inc.
$13
Epizyme, Inc.,
$12
Secura Bio, Inc.
$12
Lexicon Pharmaceuticals, Inc.
$11
Sirtex Medical Inc
$8
Top 3 companies account for 61.9% of total payments
Associated products mentioned in payments ›
ABECMA · ADCETRIS · AKYNZEO · ALUNBRIG · AYVAKIT · Alecensa · BAVENCIO · BELEODAQ · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Blincyto · Braftovi · CABLIVI · CABOMETYX · CALQUENCE · CHANTIX · CINVANTI · COPIKTRA · COSELA · CYRAMZA · Cabometyx · Cinvanti · DARZALEX · DOPTELET · Doptelet · ELIQUIS · ELITEK · EMPLICITI · ENHERTU · ERLEADA · Enhertu · Erivedge · Erleada · FARESTON · FARYDAK · FERAHEME · FLOWTRIEVER CATHETER · FOTIVDA · FOUNDATIONONE · FRUZAQLA · Fabhalta · Folotyn · GAZYVA · GILOTRIF · GIVLAARI · GammaTile · Halaven · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INQOVI · INREBIC · Imbruvica · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kadcyla · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · Lunsumio · MARGENZA · MEKINIST · MONJUVI · MONOFERRIC · MYLOTARG · NERLYNX · NINLARO · Nplate · Nubeqa · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OJJAARA · ONPATTRO · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · Odomzo · Onivyde · Optune Lua (NovoTTF-200T) · Orserdu · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · POTELIGEO · PROMACTA · PROVENGE · Padcev · Perjeta · Pomalyst · QINLOCK · REBLOZYL · RYBREVANT · RYDAPT · Rezlidhia · Rubraca · S · SANDOSTATIN LAR · SARCLISA · SCEMBLIX · SIR-Spheres Microspheres · SOMATULINE DEPOT · SUTENT · SYLVANT · Somatuline Depot · Stivarga · Sylvant · TAGRISSO · TALVEY · TASIGNA · TAZVERIK · TIBSOVO · TIVDAK · TUKYSA · Tazverik · Tecentriq · Trodelvy · UKONIQ · ULTOMIRIS · Ultomiris · VENCLEXTA · VERZENIO · VONJO · VOTRIENT · Vanflyta · Vitrakvi · Vonjo · XALKORI · XOSPATA · XPOVIO · XTANDI · Xermelo · Xospata · Xtandi · YONSA · ZEPZELCA · ZIIHERA · Zoladex · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (92%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 1% for hematology in FL.

Equivalent to $1,711 per 100 Medicare services performed
Looking for a hematology specialist in Orlando?
Compare hematologists in the Orlando area by procedure volume, costs, and industry payment transparency.
Browse hematologists nearby

Geographic Context

Hematologists within 10 mi
20
Per 100K population
1.4
County median income
$77,011
Nearest hospital
CENTRAL FLORIDA BEHAVIORAL HOSPITAL
5.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Shameem is a mixed practice specialist, with moderate Medicare volume, with speaking/promotional industry engagement in the top 1% of FL peers.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Shameem experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Shameem performed 10,200 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Shameem receive payments from pharmaceutical companies?
Yes. Dr. Shameem received a total of $668,012 from 93 companies across 1,204 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Shameem's costs compare to other hematologists in Orlando?
Dr. Shameem's average Medicare payment per service is $6. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Shameem) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →